
Bristol-Myers Squibb Co BMY.N:
BRISTOL MYERS SQUIBB AND BAIN CAPITAL CREATE NEW COMPANY DEDICATED TO DEVELOPING INNOVATIVE IMMUNOLOGY THERAPIES THAT ADDRESS THE UNMET MEDICAL NEEDS OF PATIENTS
BRISTOL-MYERS SQUIBB CO - BAIN CAPITAL LEADS $300 MILLION FINANCING COMMITMENT
BRISTOL-MYERS SQUIBB CO - BMS RETAINS NEARLY 20% EQUITY STAKE IN NEWCO